disulfiram has been researched along with Cocaine Abuse in 56 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cocaine abusers frequently report taking the drug in association with alcohol." | 9.12 | Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. ( Antonilli, L; Cioce, AM; Giudici, FD; Grassi, MC; Nencini, P, 2007) |
| "Disulfiram is a potential cocaine addiction pharmacotherapy." | 6.78 | ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. ( Hamon, SC; Harding, MJ; Kosten, TR; Nielsen, DA; Spellicy, CJ, 2013) |
| "Disulfiram is a cocaine addiction pharmacotherapy that inhibits dopamine β-hydroxylase (DβH) and reduces norepinephrine production." | 6.78 | Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation. ( Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Nielsen, DA; Shorter, D, 2013) |
| "Disulfiram has been an effective cocaine addiction pharmacotherapy, and one of its possible mechanisms of efficacy is through copper chelation and inhibition of an enzyme involved in catecholamine metabolism, dopamine β-hydroxylase (DβH), which converts dopamine to norepinephrine." | 6.78 | Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. ( Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Lappalainen, J; Nielsen, DA; Wu, G, 2013) |
| "Cocaine abusers frequently report taking the drug in association with alcohol." | 5.12 | Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. ( Antonilli, L; Cioce, AM; Giudici, FD; Grassi, MC; Nencini, P, 2007) |
| "Although disulfiram and naltrexone have been approved by the Food and Drug Administration for the treatment of alcoholism, no medications have been approved for individuals with alcohol dependence and comorbid psychiatric disorders." | 5.12 | Naltrexone and disulfiram in patients with alcohol dependence and current depression. ( Carroll, K; Levinson, C; Nich, C; Petrakis, I; Poling, J; Ralevski, E; Rounsaville, B, 2007) |
| " Recent studies have evaluated disulfiram as a treatment for individuals with comorbid alcohol and cocaine abuse." | 5.09 | Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. ( Carroll, KM; Frankforter, T; Gordon, LT; McCance-Katz, EF; Nich, C; Petrakis, IL; Rounsaville, BJ, 2000) |
| " COMT, D4 receptor, and BDNF polymorphisms are linked to methamphetamine abuse and psychosis." | 4.85 | Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. ( Haile, CN; Kosten, TA; Kosten, TR, 2009) |
| " Although alcoholism has received the most attention, nicotine, heroin, and cocaine have all been shown to be influenced by heredity." | 4.82 | Anticraving medications for relapse prevention: a possible new class of psychoactive medications. ( O'Brien, CP, 2005) |
| "Disulfiram has been beneficial in treating cocaine addiction in several studies." | 2.90 | Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. ( Hamon, SC; Harding, MJ; Kampangkaew, JP; Kosten, TR; Nielsen, DA; Nielsen, EM; Spellicy, CJ; Ye, A, 2019) |
| "CM enhances outcomes for CBT treatment of cocaine dependence, but disulfiram provided no added benefit to the combination of CM and CBT." | 2.82 | A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. ( Ball, SA; Carroll, KM; Eagan, DA; Nich, C; Petry, NM; Shi, JM, 2016) |
| "Disulfiram may be efficacious for treating cocaine dependence or abuse, possibly through inhibiting dopamine β-hydroxylase (DβH)." | 2.79 | Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. ( Chawarski, MC; Cubells, JF; George, TP; Kosten, TR; Lappalainen, J; Schottenfeld, RS, 2014) |
| "Disulfiram is a potential cocaine addiction pharmacotherapy." | 2.78 | ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. ( Hamon, SC; Harding, MJ; Kosten, TR; Nielsen, DA; Spellicy, CJ, 2013) |
| "Disulfiram is a cocaine addiction pharmacotherapy that inhibits dopamine β-hydroxylase (DβH) and reduces norepinephrine production." | 2.78 | Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation. ( Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Nielsen, DA; Shorter, D, 2013) |
| "Disulfiram has been an effective cocaine addiction pharmacotherapy, and one of its possible mechanisms of efficacy is through copper chelation and inhibition of an enzyme involved in catecholamine metabolism, dopamine β-hydroxylase (DβH), which converts dopamine to norepinephrine." | 2.78 | Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. ( Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Lappalainen, J; Nielsen, DA; Wu, G, 2013) |
| "Disulfiram is a cocaine pharmacotherapy that may act through increasing serotonin, benefiting patients with genetically low serotonin transporter levels (5-HTTLPR, S' allele carriers) and low serotonin synthesis (TPH2, A allele carriers)." | 2.77 | Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study. ( Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Nielsen, DA, 2012) |
| " Our results suggest that the use of weight-based medication doses would produce more reliable effects, consistent with weight-based dosing used in pediatrics and in preclinical research." | 2.77 | The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial. ( De La Garza, R; Haile, CN; Kosten, TR; Mahoney, JJ; Newton, TF; Nielsen, DA, 2012) |
| " In contrast, ethanol produced adverse ECG changes including QTc prolongation and a DER consisting of hypotension, tachycardia, nausea, and flushing in disulfiram-treated subjects." | 2.76 | A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram. ( Anderson, A; De La Garza, R; Elkashef, A; Kahn, R; Mojsiak, J; Murff, WL; Newton, TF; Rivera, O; Roache, JD; Wallace, CL, 2011) |
| "Disulfiram treatments also decreased cocaine clearance for the 0." | 2.73 | Disulfiram effects on responses to intravenous cocaine administration. ( Baker, JR; Jatlow, P; McCance-Katz, EF, 2007) |
| "Disulfiram has emerged as a promising treatment for cocaine dependence, but it has not yet been evaluated in general populations of cocaine users." | 2.71 | Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. ( Ball, SA; Carroll, KM; Fenton, LR; Frankforter, TL; Nich, C; Rounsaville, BJ; Shi, J, 2004) |
| "Disulfiram treatment increased plasma cocaine concentrations three to six times and significantly increased cocaine-associated cardiovascular responses, but did not significantly alter behavioral responses to cocaine." | 2.69 | Disulfiram effects on acute cocaine administration. ( Jatlow, P; Kosten, TR; McCance-Katz, EF, 1998) |
| "Disulfiram seems to be a valuable drug for the treatment of cocaine dependency." | 2.48 | [Disulfiram as a treatment for cocaine dependency]. ( De Mulder, I; Dom, G, 2012) |
| "Cocaine dependence is a public health concern and cause of significant morbidity and mortality worldwide." | 2.47 | Novel pharmacotherapeutic treatments for cocaine addiction. ( Kosten, TR; Shorter, D, 2011) |
| "Cocaine dependence is a disorder for which no pharmacological treatment of proven efficacy exists, advances in the neurobiology could guide future medication development." | 2.46 | Disulfiram for the treatment of cocaine dependence. ( Amato, L; Davoli, M; Pani, PP; Trogu, E; Vacca, R; Vecchi, S, 2010) |
| "Disulfiram treatment, despite its limitations, remains a viable option as a treatment for alcohol dependence and has shown recent promise in treating (1) those with co-morbid alcohol dependence and post-traumatic stress disorder, (2) those with co-morbid cocaine- and alcohol-dependence, and (3) those with cocaine-dependence alone." | 2.46 | Disulfiram: an old therapeutic with new applications. ( Barth, KS; Malcolm, RJ, 2010) |
| "Disulfiram has demonstrated efficacy in six randomized clinical trials for the treatment of cocaine dependence, but is rarely used in clinical settings because of safety concerns." | 2.44 | The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice. ( Lechner, W; Malcolm, R; Olive, MF, 2008) |
| "In contrast, immunotherapies for cocaine addiction are based on the blockade of cocaine effects peripherally, and as a result, prevent or at least slow the entry of cocaine into the brain." | 2.43 | Novel approaches to the treatment of cocaine addiction. ( Kosten, TR; Sofuoglu, M, 2005) |
| "Disulfiram efficacy in treatment of cocaine addiction is attributed to the inhibition of dopamine-β-hydroxylase and reduction in brain noradrenaline (NA)/dopamine (DA) ratio." | 1.38 | Disulfiram stimulates dopamine release from noradrenergic terminals and potentiates cocaine-induced dopamine release in the prefrontal cortex. ( Cadeddu, R; Devoto, P; Flore, G; Gessa, GL; Saba, P, 2012) |
| "Because DS shows treatment efficacy for cocaine addiction, results from this study suggest potential treatment agents should enhance, not attenuate, locomotor sensitization in rats." | 1.32 | Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats. ( During, MJ; Haile, CN; Jatlow, PI; Kosten, TA; Kosten, TR, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.79) | 18.2507 |
| 2000's | 24 (42.86) | 29.6817 |
| 2010's | 29 (51.79) | 24.3611 |
| 2020's | 2 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Fitzmaurice, GM | 1 |
| Lipsitz, SR | 1 |
| Weiss, RD | 1 |
| Thomas, PS | 1 |
| Nielsen, EM | 2 |
| Spellicy, CJ | 3 |
| Harding, MJ | 6 |
| Ye, A | 2 |
| Patriquin, M | 1 |
| Hamon, SC | 6 |
| Kosten, TR | 16 |
| Nielsen, DA | 7 |
| DeVito, EE | 2 |
| Dong, G | 1 |
| Kober, H | 1 |
| Xu, J | 1 |
| Carroll, KM | 15 |
| Potenza, MN | 1 |
| Buchholz, J | 1 |
| Saxon, AJ | 1 |
| Kampangkaew, JP | 1 |
| Guerrero-Solano, JL | 1 |
| Pardal-Fernández, JM | 1 |
| Baldaçara, L | 1 |
| Diniz, TA | 1 |
| Parreira, BL | 1 |
| Milhomem, JJ | 1 |
| Almeida, LJ | 1 |
| Fernandes, CC | 1 |
| Stezhka, T | 1 |
| Shorter, D | 2 |
| Huang, W | 3 |
| Kiluk, BD | 2 |
| Babuscio, TA | 3 |
| Nich, C | 13 |
| Schottenfeld, RS | 2 |
| Chawarski, MC | 2 |
| Cubells, JF | 3 |
| George, TP | 2 |
| Lappalainen, J | 2 |
| Ball, SA | 5 |
| Serafini, K | 1 |
| Malin-Mayor, B | 1 |
| Petry, NM | 1 |
| Eagan, DA | 1 |
| Shi, JM | 2 |
| Malcolm, R | 1 |
| Olive, MF | 1 |
| Lechner, W | 1 |
| Mutschler, J | 1 |
| Diehl, A | 1 |
| Kiefer, F | 1 |
| Haile, CN | 3 |
| Kosten, TA | 2 |
| Kampman, KM | 3 |
| Kaul, S | 1 |
| Williams, TD | 1 |
| Lunte, CE | 1 |
| Faiman, MD | 1 |
| Gaval-Cruz, M | 1 |
| Weinshenker, D | 2 |
| Pani, PP | 1 |
| Trogu, E | 1 |
| Vacca, R | 1 |
| Amato, L | 1 |
| Vecchi, S | 1 |
| Davoli, M | 1 |
| Barth, KS | 1 |
| Malcolm, RJ | 1 |
| Simkin, DR | 1 |
| Grenoble, S | 1 |
| Oliveto, A | 1 |
| Poling, J | 2 |
| Mancino, MJ | 1 |
| Feldman, Z | 1 |
| Pruzinsky, R | 1 |
| Gonsai, K | 1 |
| Cargile, C | 1 |
| Sofuoglu, M | 3 |
| Chopra, MP | 1 |
| Gonzalez-Haddad, G | 1 |
| Roache, JD | 1 |
| Kahn, R | 1 |
| Newton, TF | 2 |
| Wallace, CL | 1 |
| Murff, WL | 1 |
| De La Garza, R | 2 |
| Rivera, O | 1 |
| Anderson, A | 1 |
| Mojsiak, J | 1 |
| Elkashef, A | 1 |
| Devoto, P | 1 |
| Flore, G | 1 |
| Saba, P | 1 |
| Cadeddu, R | 1 |
| Gessa, GL | 1 |
| De Mulder, I | 1 |
| Dom, G | 1 |
| Grau-López, L | 1 |
| Roncero, C | 1 |
| Navarro, MC | 1 |
| Casas, M | 1 |
| Eagan, D | 1 |
| Herdener, M | 1 |
| Oppliger, R | 1 |
| Stohler, R | 1 |
| Caflisch, C | 1 |
| Wu, G | 1 |
| Mahoney, JJ | 1 |
| Pantalon, MV | 1 |
| Frankforter, T | 3 |
| During, MJ | 1 |
| Jatlow, PI | 1 |
| Milligan, CO | 1 |
| Fenton, LR | 1 |
| Frankforter, TL | 2 |
| Shi, J | 1 |
| Rounsaville, BJ | 5 |
| Jofre-Bonet, M | 1 |
| Sindelar, JL | 1 |
| Petrakis, IL | 3 |
| McCance-Katz, EF | 4 |
| O'Brien, CP | 3 |
| Suh, JJ | 1 |
| Pettinati, HM | 2 |
| Baker, JR | 1 |
| Jatlow, P | 2 |
| Grassi, MC | 1 |
| Cioce, AM | 1 |
| Giudici, FD | 1 |
| Antonilli, L | 1 |
| Nencini, P | 1 |
| Petrakis, I | 1 |
| Ralevski, E | 1 |
| Levinson, C | 1 |
| Carroll, K | 1 |
| Rounsaville, B | 1 |
| Preti, A | 1 |
| Lynch, KG | 1 |
| Xie, H | 1 |
| Dackis, C | 1 |
| Rabinowitz, AR | 1 |
| Gordon, LT | 1 |
| Pakes, J | 1 |
| McCance, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Disulfiram for Treating Cocaine Dependence in Individuals With Different Dopamine Beta Hydroxylase (DBH) Genes[NCT00149630] | Phase 2 | 93 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Maximizing the Efficacy of Cognitive Behavioral Therapy With Medication and Contingency Management[NCT00350870] | Phase 1 | 181 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Laboratory Models of Cocaine Self-administration[NCT00729300] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer[NCT03323346] | Phase 2 | 150 participants (Anticipated) | Interventional | 2017-09-29 | Recruiting | ||
| Two Medications, Disulfiram and Naltrexone, in the Treatment of Patients With Both Cocaine and Alcohol Dependence[NCT00142844] | Phase 2 | 208 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Treatment retention for full 12 weeks of study. (NCT00149630)
Timeframe: 12 weeks
| Intervention | % of subjects who complete 12 wks study (Number) |
|---|---|
| Disulfiram | 77 |
| Placebo | 87 |
(NCT00149630)
Timeframe: Thrice weekly, baseline through week 14.
| Intervention | % cocaine + urines over 2 week blocks (Mean) |
|---|---|
| Placebo CC | 84 |
| Placebo CT/TT | 68 |
| Disulfiram CC | 56 |
| Disulfiram CT/TT | 67 |
Self-reports of substance use will be documented at each contact via the Substance Use Calendar. Similar to the Form-90 and the Time Line Follow-Back, which have been shown to be reliable and valid instruments for monitoring substance use and other outcomes in longitudinal studies202-204, the Substance Use Calendar allows a flexible, continuous evaluation of substance use on a daily basis. (NCT00350870)
Timeframe: 12 weeks
| Intervention | percentage of days abstinent (Mean) |
|---|---|
| Placebo | 72.2 |
| Disulfiram | 79.2 |
| Placebo Plus Contingency Management | 91.1 |
| Disulfiram Plus Contingency Management | 69.6 |
We will use the Roche onsite TESTCUP system for detection of cocaine, methamphetamine, THC, benzodiazepenes, and opioids. (NCT00350870)
Timeframe: 12 weeks
| Intervention | percentage of negative urines (Mean) |
|---|---|
| Placebo | 17.9 |
| Disulfiram | 30.1 |
| Placebo Plus Contingency Management | 53 |
| Disulfiram Plus Contingency Management | 42.6 |
The reinforcing effects of cocaine were determined using a self-administration procedure in which subjects choose to take previously sampled doses of cocaine or cash of increasing monetary value. The mean number of cocaine choices across each drug condition (i.e., placebo and disulfiram) is reported. (NCT00729300)
Timeframe: 4 days
| Intervention | cocaine choices/participant (Mean) |
|---|---|
| Placebo | 2.5 |
| Disulfiram Treatment Group | 4.8 |
17 reviews available for disulfiram and Cocaine Abuse
| Article | Year |
|---|---|
Medications to treat cocaine use disorders: current options.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Central Nervous System Stimulants; Coc | 2019 |
The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice.
Topics: Alcohol Deterrents; Alcoholism; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topi | 2008 |
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
Topics: Amphetamine; Amphetamine-Related Disorders; Cocaine-Related Disorders; Disulfiram; Dopamine Uptake I | 2009 |
New medications for the treatment of cocaine dependence.
Topics: Clinical Trials as Topic; Cocaine-Related Disorders; Disulfiram; GABA Agents; Humans; Secondary Prev | 2009 |
mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse.
Topics: Animals; Clinical Trials as Topic; Cocaine-Related Disorders; Disulfiram; Dopamine beta-Hydroxylase; | 2009 |
Disulfiram for the treatment of cocaine dependence.
Topics: Cocaine-Related Disorders; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Randomized Controll | 2010 |
Disulfiram: an old therapeutic with new applications.
Topics: Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Brain Chemistry; Cocaine- | 2010 |
Pharmacotherapies for adolescent substance use disorders.
Topics: Adolescent; Alcohol Deterrents; Alcoholism; Cocaine-Related Disorders; Disulfiram; Humans; Marijuana | 2010 |
Novel pharmacotherapeutic treatments for cocaine addiction.
Topics: Berberine Alkaloids; Clinical Trials as Topic; Cocaine-Related Disorders; Disulfiram; Dopamine Agoni | 2011 |
[Disulfiram as a treatment for cocaine dependency].
Topics: Cocaine-Related Disorders; Disulfiram; Dopamine beta-Hydroxylase; Enzyme Inhibitors; Humans; Randomi | 2012 |
[Treating cocaine addiction].
Topics: Acetylcysteine; Alcohol Deterrents; Baclofen; Benzhydryl Compounds; Central Nervous System Stimulant | 2012 |
Sex differences in cocaine-dependent individuals' response to disulfiram treatment.
Topics: Adult; Cocaine-Related Disorders; Disulfiram; Drug Therapy, Combination; Enzyme Inhibitors; Female; | 2004 |
Novel approaches to the treatment of cocaine addiction.
Topics: Adrenergic Agents; Animals; Brain; Cocaine-Related Disorders; Disulfiram; Dopamine; Dopamine Agents; | 2005 |
Anticraving medications for relapse prevention: a possible new class of psychoactive medications.
Topics: Alcoholism; Behavior, Addictive; Bupropion; Cocaine-Related Disorders; Disulfiram; Humans; Naltrexon | 2005 |
Emerging pharmacological strategies in the fight against cocaine addiction.
Topics: Adrenergic beta-Antagonists; Animals; Benzhydryl Compounds; Brain; Central Nervous System Stimulants | 2006 |
The status of disulfiram: a half of a century later.
Topics: Alcohol Deterrents; Alcoholism; Cocaine-Related Disorders; Disulfiram; Drug Implants; History, 20th | 2006 |
New developments in the pharmacotherapy of cocaine abuse.
Topics: Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Cocaine-Related Disorders; Comorbidity; Di | 2007 |
28 trials available for disulfiram and Cocaine Abuse
| Article | Year |
|---|---|
The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients.
Topics: Adult; Alleles; Cocaine; Cocaine-Related Disorders; Disulfiram; Female; Genotype; Humans; Male; Meth | 2021 |
Functional neural changes following behavioral therapies and disulfiram for cocaine dependence.
Topics: Adult; Brain; Brain Mapping; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Combined Modal | 2017 |
Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Adult; Alleles; Biomarkers; Cocaine-Related Disorders; Disulf | 2019 |
Could disulfiram be a new treatment for crack cocaine dependence?: a pilot study.
Topics: Adolescent; Adult; Cocaine-Related Disorders; Crack Cocaine; Disulfiram; Humans; Male; Medication Ad | 2013 |
ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.
Topics: Adult; Alleles; Cocaine-Related Disorders; Disulfiram; Female; Genotype; Humans; Male; Methadone; Po | 2013 |
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.
Topics: Adult; Alcohol Deterrents; Alleles; Cocaine-Related Disorders; Disulfiram; Dopamine beta-Hydroxylase | 2013 |
Smokers versus snorters: do treatment outcomes differ according to route of cocaine administration?
Topics: Administration, Inhalation; Administration, Intranasal; Adult; Alcoholism; Cocaine; Cocaine-Related | 2013 |
Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcoholism; Alleles; Buprenorphine; Cocaine-Related Disorders | 2014 |
Gender differences in clinical outcomes for cocaine dependence: randomized clinical trials of behavioral therapy and disulfiram.
Topics: Adult; Behavior Therapy; Cocaine-Related Disorders; Disulfiram; Female; Follow-Up Studies; Humans; M | 2014 |
Prompted to treatment by the criminal justice system: Relationships with treatment retention and outcome among cocaine users.
Topics: Adult; Behavior Therapy; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Combined Modality | 2015 |
A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence.
Topics: Adult; Alcohol Deterrents; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Combined Modalit | 2016 |
Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients.
Topics: Adult; Alcohol Drinking; Cocaine; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Disulfira | 2011 |
A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram.
Topics: Adult; Alcohol Deterrents; Blood Pressure; Central Nervous System Depressants; Cocaine; Cocaine-Rela | 2011 |
Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Cocaine-Related Disorders; Counseling; Demography; Diag | 2012 |
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.
Topics: Adult; Cocaine-Related Disorders; Disulfiram; Dopamine beta-Hydroxylase; Drug Therapy, Combination; | 2013 |
Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study.
Topics: Adult; Alleles; Cocaine; Cocaine-Related Disorders; Comorbidity; Disulfiram; Female; Genetic Carrier | 2012 |
The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial.
Topics: Adult; Choice Behavior; Cocaine; Cocaine-Related Disorders; Cross-Over Studies; Disulfiram; Dose-Res | 2012 |
The URICA as a measure of motivation to change among treatment-seeking individuals with concurrent alcohol and cocaine problems.
Topics: Adult; Alcohol Deterrents; Alcoholism; Cocaine-Related Disorders; Disulfiram; Female; Humans; Male; | 2002 |
Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.
Topics: Adult; Alcohol Deterrents; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Disulfiram; Doub | 2004 |
Cost effectiveness of disulfiram: treating cocaine use in methadone-maintained patients.
Topics: Adult; Analgesics, Opioid; Cocaine-Related Disorders; Connecticut; Cost-Benefit Analysis; Disulfiram | 2004 |
Disulfiram effects on responses to intravenous cocaine administration.
Topics: Adult; Alcohol Deterrents; Cocaine; Cocaine-Related Disorders; Disulfiram; Double-Blind Method; Fema | 2007 |
Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study.
Topics: Adult; Cocaine; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2007 |
Naltrexone and disulfiram in patients with alcohol dependence and current depression.
Topics: Alcohol Deterrents; Alcoholism; Bipolar Disorder; Cocaine-Related Disorders; Comorbidity; Connecticu | 2007 |
A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence.
Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Cocaine-Related Disorders; Disulfiram; Doub | 2008 |
Disulfiram effects on acute cocaine administration.
Topics: Acute Disease; Adult; Alcohol Deterrents; Cholinesterases; Cocaine-Related Disorders; Disulfiram; Do | 1998 |
Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts.
Topics: Cocaine-Related Disorders; Disulfiram; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Male; | 2000 |
Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial.
Topics: Adult; Alcohol Deterrents; Buprenorphine; Chi-Square Distribution; Cocaine-Related Disorders; Disulf | 2000 |
One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment.
Topics: Adult; Alcohol Deterrents; Alcoholism; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Comb | 2000 |
11 other studies available for disulfiram and Cocaine Abuse
| Article | Year |
|---|---|
Within-treatment frequency of use versus abstinence as a predictor of longitudinal post-treatment follow-up assessments of drug use.
Topics: Adult; Cocaine; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Disulfiram; Female; Follow- | 2020 |
[Symmetrical bilateral sural nerve mononeuropathy in an alcoholic patient].
Topics: Adult; Alcoholic Neuropathy; Alcoholism; Axons; Cocaine-Related Disorders; Disulfiram; Humans; Male; | 2013 |
Disulfiram: old addiction drug gains new support.
Topics: Cocaine-Related Disorders; Disulfiram; Dopamine beta-Hydroxylase; Enzyme Inhibitors; Humans; Randomi | 2013 |
Pronounced paranoia as a result of cocaine-disulfiram interaction: case report and mode of action.
Topics: Administration, Intranasal; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Cocaine; Cocain | 2009 |
LC-MS/MS determination of carbamathione in microdialysis samples from rat brain and plasma.
Topics: Animals; Brain; Chromatography, Liquid; Cocaine-Related Disorders; Disulfiram; Glutathione; Male; Mi | 2010 |
Cocaine sobers up.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Animals; Cocaine-Related Disorders; D | 2010 |
Disulfiram stimulates dopamine release from noradrenergic terminals and potentiates cocaine-induced dopamine release in the prefrontal cortex.
Topics: Animals; Brain; Cocaine; Cocaine-Related Disorders; Disulfiram; Dopamine; Dopamine beta-Hydroxylase; | 2012 |
Psychosis induced by the interaction between disulfiram and methylphenidate may be dose dependent.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Cocaine-Related Disorders; Disulfiram; Dopamin | 2012 |
Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats.
Topics: Animals; Cocaine; Cocaine-Related Disorders; Disulfiram; Dopamine Uptake Inhibitors; Enzyme Inhibito | 2003 |
Ethnic differences in substance abuse treatment retention, compliance, and outcome from two clinical trials.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Black People; Cocaine-Related Disorde | 2004 |
Disulfiram and buprenorphine for treating cocaine addiction.
Topics: Buprenorphine; Cocaine-Related Disorders; Disulfiram; Humans | 2000 |